Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Hochhaus

Showing results (1-10 of 523) with videos related to

Pageof 53
Sort By:
Seminars in Hematology|June 5, 2003
Cytogenetic and molecular mechanisms of resistance to imatinibAndreas Hochhaus
Journal of the National Comprehensive Cancer Network : JNCCN|August 9, 2008
First-Line management of CML: a state of the art reviewAndreas Hochhaus
Hematology. American Society of Hematology. Education Program|December 14, 2011
Educational session: managing chronic myeloid leukemia as a chronic diseaseAndreas Hochhaus
Onkologie|January 16, 2009
Prognostic factors in chronic myeloid leukemia (CML)Andreas Hochhaus
Expert Opinion on Pharmacotherapy|November 27, 2007
Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failureAndreas Hochhaus
Expert Review of Anticancer Therapy|November 21, 2007
Management of Bcr-Abl-positive leukemias with dasatinibAndreas Hochhaus
Methods in Molecular Medicine|March 21, 2002
Detection and quantification of leukemia-specific rearrangementsAndreas Hochhaus
Blood|March 1, 2014
Optimizing tolerability of TKI therapy in CMLAndreas Hochhaus
Best Practice & Research. Clinical Haematology|May 4, 2002
Minimal residual disease in chronic myeloid leukaemia patientsAndreas Hochhaus
Hematology/Oncology Clinics of North America|July 24, 2004
Clinical resistance to imatinib: mechanisms and implicationsAndreas Hochhaus, Timothy Hughes
Pageof 53

Showing results (1-10 of 523) with videos related to

Sort By:
Pageof 53
Seminars in Hematology|June 5, 2003
Cytogenetic and molecular mechanisms of resistance to imatinibAndreas Hochhaus
Journal of the National Comprehensive Cancer Network : JNCCN|August 9, 2008
First-Line management of CML: a state of the art reviewAndreas Hochhaus
Hematology. American Society of Hematology. Education Program|December 14, 2011
Educational session: managing chronic myeloid leukemia as a chronic diseaseAndreas Hochhaus
Onkologie|January 16, 2009
Prognostic factors in chronic myeloid leukemia (CML)Andreas Hochhaus
Expert Opinion on Pharmacotherapy|November 27, 2007
Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failureAndreas Hochhaus
Expert Review of Anticancer Therapy|November 21, 2007
Management of Bcr-Abl-positive leukemias with dasatinibAndreas Hochhaus
Methods in Molecular Medicine|March 21, 2002
Detection and quantification of leukemia-specific rearrangementsAndreas Hochhaus
Blood|March 1, 2014
Optimizing tolerability of TKI therapy in CMLAndreas Hochhaus
Best Practice & Research. Clinical Haematology|May 4, 2002
Minimal residual disease in chronic myeloid leukaemia patientsAndreas Hochhaus
Hematology/Oncology Clinics of North America|July 24, 2004
Clinical resistance to imatinib: mechanisms and implicationsAndreas Hochhaus, Timothy Hughes
Pageof 53